ID   FMO2_HUMAN              Reviewed;         471 AA.
AC   Q99518; Q5EBX4; Q86U73; Q9BRX1;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   05-APR-2011, sequence version 4.
DT   15-MAR-2017, entry version 164.
DE   RecName: Full=Dimethylaniline monooxygenase [N-oxide-forming] 2;
DE            EC=1.14.13.8;
DE   AltName: Full=Dimethylaniline oxidase 2;
DE   AltName: Full=FMO 1B1;
DE   AltName: Full=Pulmonary flavin-containing monooxygenase 2;
DE            Short=FMO 2;
GN   Name=FMO2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, ALLELE FMO2*1 TYR-471 INS, AND POLYMORPHISM.
RC   TISSUE=Lung;
RX   PubMed=9804831; DOI=10.1074/jbc.273.46.30599;
RA   Dolphin C.T., Beckett D.J., Janmohamed A., Cullingford T.E.,
RA   Smith R.L., Shephard E.A., Phillips I.R.;
RT   "The flavin-containing monooxygenase 2 gene (FMO2) of humans, but not
RT   of other primates, encodes a truncated, nonfunctional protein.";
RL   J. Biol. Chem. 273:30599-30607(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], ALLELE FMO2*1 TYR-471 INS, AND
RP   VARIANTS GLY-36; TYR-69; SER-81; SER-182; LEU-195; GLN-238; GLY-314;
RP   THR-391 AND LYS-413.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2005) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND ALLELE FMO2*1 TYR-471 INS.
RC   TISSUE=Skeletal muscle;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   SUBCELLULAR LOCATION, TISSUE SPECIFICITY, ALLELE FMO2*1 TYR-471 INS,
RP   AND POLYMORPHISM.
RX   PubMed=11042094; DOI=10.1006/taap.2000.9050;
RA   Whetstine J.R., Yueh M.F., McCarver D.G., Williams D.E., Park C.S.,
RA   Kang J.H., Cha Y.N., Dolphin C.T., Shephard E.A., Phillips I.R.,
RA   Hines R.N.;
RT   "Ethnic differences in human flavin-containing monooxygenase 2 (FMO2)
RT   polymorphisms: detection of expressed protein in African-Americans.";
RL   Toxicol. Appl. Pharmacol. 168:216-224(2000).
RN   [8]
RP   SUMOYLATION.
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20388717; DOI=10.1074/jbc.M110.106955;
RA   Blomster H.A., Imanishi S.Y., Siimes J., Kastu J., Morrice N.A.,
RA   Eriksson J.E., Sistonen L.;
RT   "In vivo identification of sumoylation sites by a signature tag and
RT   cysteine-targeted affinity purification.";
RL   J. Biol. Chem. 285:19324-19329(2010).
RN   [9]
RP   VARIANTS GLY-36; ILE-59; SER-182; LEU-195; GLN-238; THR-391 AND
RP   LYS-413.
RX   PubMed=12527699; DOI=10.1124/dmd.31.2.187;
RA   Furnes B., Feng J., Sommer S.S., Schlenk D.;
RT   "Identification of novel variants of the flavin-containing
RT   monooxygenase gene family in African Americans.";
RL   Drug Metab. Dispos. 31:187-193(2003).
RN   [10]
RP   ALLELE FMO2*1 TYR-471 INS, AND POLYMORPHISM.
RX   PubMed=18794725; DOI=10.1097/FPC.0b013e3283097311;
RA   Veeramah K.R., Thomas M.G., Weale M.E., Zeitlyn D., Tarekegn A.,
RA   Bekele E., Mendell N.R., Shephard E.A., Bradman N., Phillips I.R.;
RT   "The potentially deleterious functional variant flavin-containing
RT   monooxygenase 2*1 is at high frequency throughout sub-Saharan
RT   Africa.";
RL   Pharmacogenet. Genomics 18:877-886(2008).
CC   -!- FUNCTION: Catalyzes the N-oxidation of certain primary alkylamines
CC       to their oximes via an N-hydroxylamine intermediate. Inactive
CC       toward certain tertiary amines, such as imipramine or
CC       chloropromazine. Can catalyze the S-oxidation of methimazole. The
CC       truncated form is catalytically inactive.
CC       {ECO:0000269|PubMed:9804831}.
CC   -!- CATALYTIC ACTIVITY: N,N-dimethylaniline + NADPH + O(2) = N,N-
CC       dimethylaniline N-oxide + NADP(+) + H(2)O.
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC   -!- SUBCELLULAR LOCATION: Microsome membrane. Endoplasmic reticulum
CC       membrane.
CC   -!- TISSUE SPECIFICITY: Expressed in lung (at protein level).
CC       Expressed predominantly in lung, and at a much lesser extent in
CC       kidney. Also expressed in fetal lung, but not in liver, kidney and
CC       brain. {ECO:0000269|PubMed:11042094, ECO:0000269|PubMed:9804831}.
CC   -!- PTM: The truncated form is probably unable to fold correctly and
CC       is rapidly degraded.
CC   -!- PTM: FMO2*1 is sumoylated at 'Lys-492'.
CC       {ECO:0000269|PubMed:20388717}.
CC   -!- POLYMORPHISM: The sequence shown is that of the allele FMO2*2A.
CC       There are two alleles; one major, FMO2*2A (truncated form) and one
CC       minor, FMO2*1 (full-length form similar to the protein found in
CC       other mammals) (PubMed:9804831). A nonsense mutation transforms
CC       the Gln-472 of FMO2*1 in a premature stop codon (PubMed:9804831).
CC       FMO2*2A occurs in essentially 100% of Caucasians and Asians
CC       (PubMed:9804831). FMO2*1 is present at a frequency of
CC       approximately 4% to 13% in the sample of population of African
CC       descent (PubMed:9804831, PubMed:11042094, PubMed:18794725).
CC       FMO2*2A is catalytically inactive (PubMed:9804831).
CC       {ECO:0000269|PubMed:11042094, ECO:0000269|PubMed:18794725,
CC       ECO:0000269|PubMed:9804831}.
CC   -!- SIMILARITY: Belongs to the FMO family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fmo2/";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y09267; CAA70462.1; -; mRNA.
DR   EMBL; AY916056; AAW82431.1; -; Genomic_DNA.
DR   EMBL; BT006979; AAP35625.1; -; mRNA.
DR   EMBL; AL021026; CAA15910.1; -; Genomic_DNA.
DR   EMBL; CH471067; EAW90889.1; -; Genomic_DNA.
DR   EMBL; BC005894; AAH05894.1; -; mRNA.
DR   RefSeq; NP_001451.2; NM_001460.4.
DR   UniGene; Hs.144912; -.
DR   ProteinModelPortal; Q99518; -.
DR   BioGrid; 108614; 1.
DR   IntAct; Q99518; 2.
DR   STRING; 9606.ENSP00000209929; -.
DR   ChEMBL; CHEMBL3542432; -.
DR   iPTMnet; Q99518; -.
DR   PhosphoSitePlus; Q99518; -.
DR   DMDM; 327478599; -.
DR   PaxDb; Q99518; -.
DR   PeptideAtlas; Q99518; -.
DR   PRIDE; Q99518; -.
DR   DNASU; 2327; -.
DR   Ensembl; ENST00000209929; ENSP00000209929; ENSG00000094963.
DR   GeneID; 2327; -.
DR   KEGG; hsa:2327; -.
DR   UCSC; uc057ngi.1; human.
DR   CTD; 2327; -.
DR   DisGeNET; 2327; -.
DR   GeneCards; FMO2; -.
DR   HGNC; HGNC:3770; FMO2.
DR   HPA; HPA028261; -.
DR   MIM; 603955; gene.
DR   neXtProt; NX_Q99518; -.
DR   PharmGKB; PA164741534; -.
DR   eggNOG; KOG1399; Eukaryota.
DR   eggNOG; COG2072; LUCA.
DR   HOGENOM; HOG000076537; -.
DR   HOVERGEN; HBG002037; -.
DR   InParanoid; Q99518; -.
DR   KO; K00485; -.
DR   OrthoDB; EOG091G0465; -.
DR   PhylomeDB; Q99518; -.
DR   TreeFam; TF105285; -.
DR   BRENDA; 1.14.13.8; 2681.
DR   Reactome; R-HSA-217271; FMO oxidises nucleophiles.
DR   ChiTaRS; FMO2; human.
DR   GeneWiki; FMO2; -.
DR   GenomeRNAi; 2327; -.
DR   PRO; PR:Q99518; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000094963; -.
DR   CleanEx; HS_FMO2; -.
DR   ExpressionAtlas; Q99518; baseline and differential.
DR   Genevisible; Q99518; HS.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; IEA:UniProtKB-KW.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0031090; C:organelle membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IEA:InterPro.
DR   GO; GO:0004497; F:monooxygenase activity; TAS:Reactome.
DR   GO; GO:0004499; F:N,N-dimethylaniline monooxygenase activity; IDA:BHF-UCL.
DR   GO; GO:0050661; F:NADP binding; IEA:InterPro.
DR   GO; GO:0017144; P:drug metabolic process; IDA:BHF-UCL.
DR   GO; GO:0006739; P:NADP metabolic process; IDA:BHF-UCL.
DR   GO; GO:0070995; P:NADPH oxidation; IDA:UniProtKB.
DR   GO; GO:0006082; P:organic acid metabolic process; IDA:BHF-UCL.
DR   GO; GO:0072592; P:oxygen metabolic process; IEA:Ensembl.
DR   GO; GO:0009404; P:toxin metabolic process; IDA:BHF-UCL.
DR   GO; GO:0006805; P:xenobiotic metabolic process; IDA:BHF-UCL.
DR   Gene3D; 3.50.50.60; -; 2.
DR   InterPro; IPR012143; DiMe-aniline_mOase.
DR   InterPro; IPR023753; FAD/NAD-binding_dom.
DR   InterPro; IPR000960; Flavin_mOase.
DR   InterPro; IPR020946; Flavin_mOase-like.
DR   InterPro; IPR002254; Flavin_mOase_2.
DR   Pfam; PF00743; FMO-like; 1.
DR   PIRSF; PIRSF000332; FMO; 1.
DR   PRINTS; PR00370; FMOXYGENASE.
DR   PRINTS; PR01122; FMOXYGENASE2.
DR   SUPFAM; SSF51905; SSF51905; 2.
PE   1: Evidence at protein level;
KW   Acetylation; Complete proteome; Endoplasmic reticulum; FAD;
KW   Flavoprotein; Magnesium; Membrane; Microsome; Monooxygenase; NADP;
KW   Oxidoreductase; Polymorphism; Reference proteome; Transmembrane;
KW   Ubl conjugation.
FT   INIT_MET      1      1       Removed. {ECO:0000250|UniProtKB:P17635}.
FT   CHAIN         2    471       Dimethylaniline monooxygenase [N-oxide-
FT                                forming] 2.
FT                                /FTId=PRO_0000147646.
FT   NP_BIND       9     14       FAD. {ECO:0000255}.
FT   NP_BIND     191    196       NADP. {ECO:0000255}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000250|UniProtKB:P17635}.
FT   VARIANT      36     36       D -> G (in dbSNP:rs2020870).
FT                                {ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_014840.
FT   VARIANT      59     59       V -> I (in dbSNP:rs55708639).
FT                                {ECO:0000269|PubMed:12527699}.
FT                                /FTId=VAR_015361.
FT   VARIANT      69     69       F -> Y (in dbSNP:rs28745274).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_022185.
FT   VARIANT      81     81       F -> S (in dbSNP:rs2020860).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_014841.
FT   VARIANT     182    182       F -> S (in dbSNP:rs2307492).
FT                                {ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_014842.
FT   VARIANT     195    195       S -> L (in dbSNP:rs2020862).
FT                                {ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_014843.
FT   VARIANT     238    238       R -> Q (in dbSNP:rs28369895).
FT                                {ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_015362.
FT   VARIANT     314    314       E -> G (in dbSNP:rs2020863).
FT                                {ECO:0000269|Ref.2}.
FT                                /FTId=VAR_022186.
FT   VARIANT     391    391       R -> T (in dbSNP:rs28369899).
FT                                {ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_015363.
FT   VARIANT     413    413       N -> K (in dbSNP:rs2020865).
FT                                {ECO:0000269|PubMed:12527699,
FT                                ECO:0000269|Ref.2}.
FT                                /FTId=VAR_014844.
FT   VARIANT     471    471       Y -> YQYRLVGPGQWEGARNAIFTQKQRILKPLKTRALKD
FT                                SSNFSVSFLLKILGLLAVVVAFFCQLQWS (in allele
FT                                FMO2*1).
FT                                /FTId=VAR_064887.
FT   CONFLICT     71     71       D -> DD (in Ref. 2; AAW82431).
FT                                {ECO:0000305}.
SQ   SEQUENCE   471 AA;  53644 MW;  AF87E304131BA703 CRC64;
     MAKKVAVIGA GVSGLISLKC CVDEGLEPTC FERTEDIGGV WRFKENVEDG RASIYQSVVT
     NTSKEMSCFS DFPMPEDFPN FLHNSKLLEY FRIFAKKFDL LKYIQFQTTV LSVRKCPDFS
     SSGQWKVVTQ SNGKEQSAVF DAVMVCSGHH ILPHIPLKSF PGMERFKGQY FHSRQYKHPD
     GFEGKRILVI GMGNSGSDIA VELSKNAAQV FISTRHGTWV MSRISEDGYP WDSVFHTRFR
     SMLRNVLPRT AVKWMIEQQM NRWFNHENYG LEPQNKYIMK EPVLNDDVPS RLLCGAIKVK
     STVKELTETS AIFEDGTVEE NIDVIIFATG YSFSFPFLED SLVKVENNMV SLYKYIFPAH
     LDKSTLACIG LIQPLGSIFP TAELQARWVT RVFKGLCSLP SERTMMMDII KRNEKRIDLF
     GESQSQTLQT NYVDYLDELA LEIGAKPDFC SLLFKDPKLA VRLYFGPCNS Y
//
